Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

T7572

Sigma-Aldrich

Thrombin from human plasma

400-1000 NIH units/mg protein

Synonym(s):

Factor IIa

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
9002-04-4
Enzyme Commission number:
3.4.21.5 (BRENDA, IUBMB)
EC Number:
232-648-7
MDL number:
MFCD00082072
UNSPSC Code:
12352204
NACRES:
NA.54
Pricing and availability is not currently available.

form

lyophilized powder

Quality Level

200

specific activity

400-1000 NIH units/mg protein

impurities

HIV, hepatitis B and hepatitis C, tested negative

UniProt accession no.

P00734

storage temp.

−20°C

Gene Information

human ... F2(2147)

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
819815819813814688
TOYOPEARL® HW-65S Bulk Media phase hydroxylated methacrylic polymer, bottle of 250 mL, 20-40 μm

807467

TOYOPEARL® HW-65S Bulk Media

TOYOPEARL® HW-65S Bulk Media phase hydroxylated methacrylic polymer, bottle of 150 mL, 30 μm particle size

819815

TOYOPEARL® HW-65S Bulk Media

TOYOPEARL® HW-55S Bulk Media phase hydroxylated methacrylic polymer, bottle of 150 mL, 30 μm particle size

819813

TOYOPEARL® HW-55S Bulk Media

vibrant-m

814688

TOYOPEARL® HW-65S Bulk Media

separation technique

size exclusion (SEC)

separation technique

size exclusion (SEC)

separation technique

size exclusion (SEC)

separation technique

size exclusion (SEC)

particle size

20-40 μm

particle size

30 μm

particle size

30 μm

particle size

30 μm

matrix active group

hydroxylated methacrylic polymer phase

matrix active group

hydroxylated methacrylic polymer phase

matrix active group

hydroxylated methacrylic polymer phase

matrix active group

hydroxylated methacrylic polymer phase

technique(s)

LPLC: suitable

technique(s)

LPLC: suitable

technique(s)

LPLC: suitable

technique(s)

LPLC: suitable

product line

TOYOPEARL®

product line

TOYOPEARL®

product line

TOYOPEARL®

product line

TOYOPEARL®

General description

Lyophilized powder containing sucrose, sodium chloride and Tris.
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects. [1]

Application

Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to assess an innovative flow cytometric approach for small-size platelet microparticles. [2]

Biochem/physiol Actions

Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.

Unit Definition

Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard

Analysis Note

The NIH assay procedure uses 0.2 ml diluted plasma (1:1 with saline) as a substrate and 0.1ml of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.

Other Notes

View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Regulatory Information

常规特殊物品

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    0000424707
    0000424707
    0000375453
    0000310512
    0000310512

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Silvia Montoro-García et al.
    Thrombosis and haemostasis, 108(2), 373-383 (2012-06-29)
    Microparticles (MPs) are small submicron membrane-derived vesicles shed from a variety of cells and they have been implicated in different disorders. Accordingly, understanding of physiological characteristics of MPs and improvement of methods of their quantification are important for further advance
    At the cutting edge: conformational PARtiality.
    T Madhusudhan et al.
    Journal of thrombosis and haemostasis : JTH, 10(8), 1672-1674 (2012-06-30)
    Jawed Fareed et al.
    Annual review of pharmacology and toxicology, 52, 79-99 (2011-08-09)
    Since the discovery of heparin nearly a century ago, there have been large gaps in the development of anticoagulants. The discovery of warfarin was the first step toward using oral anticoagulants, but warfarin use has been associated with its own
    Lukas Graf et al.
    Swiss medical weekly, 142, w13684-w13684 (2012-10-06)
    New oral anticoagulants used as single target inhibitors of coagulation enzymes have been developed and tested in extensive trial programmes. Results of most of these trials showed non-inferior and/or superior efficacy and safety compared to standard treatment with LMWH or
    Herbert Nar
    Trends in pharmacological sciences, 33(5), 279-288 (2012-04-17)
    The quest for novel medications to treat thromboembolic disorders such as venous thrombosis, pulmonary embolism and stroke received a boost when the 3D structures of two major players in the blood coagulation cascade were determined in 1989 and 1993. Structure-guided
    View All Related Papers

    Articles

    Thrombin Factor IIa

    Thrombin Factor IIa is an endolytic serine protease that selectively cleaves the Arg--Gly bonds of fibrinogen to form fibrin and release fibrinopeptides A and B.

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service